

## **SUPPLEMENTARY MATERIAL**

### **Budget Impact Analysis of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) for Recurrent *Clostridioides difficile* Infection in the United States**

Michele Wilson, PhD,<sup>1</sup> Yoav Golan, MD,<sup>2</sup> Dianne Nguyen, MD,<sup>3</sup> Morteza Yazdani, PhD,<sup>4</sup>  
Alpesh N. Amin, MD<sup>5</sup>

<sup>1</sup>RTI Health Solutions, Research Triangle Park, NC, USA

<sup>2</sup>Tufts Medical Center, Boston, MA, USA

<sup>3</sup>Nestlé Health Science, Bridgewater, NJ, USA

<sup>4</sup>Nestlé Health Science, Lausanne, Switzerland

<sup>5</sup>University of California, Irvine, CA, USA

#### **Corresponding Author:**

Morteza Yazdani, PhD


Email: [morteza.yazdani1@nestle.com](mailto:morteza.yazdani1@nestle.com)

**Supplementary Table S1** Percentage of antibiotic use by recurrence

|                        | Percentage use by recurrence |                   |                  |                   |
|------------------------|------------------------------|-------------------|------------------|-------------------|
|                        | First recurrence             | Second recurrence | Third recurrence | Fourth recurrence |
| Antibacterial product  |                              |                   |                  |                   |
| Fidaxomicin 200 mg     | 6%                           | 13%               | 13%              | 13%               |
| Metronidazole 500 mg   | 9%                           | 4%                | 2%               | 2%                |
| Vancomycin 125 mg      | 72%                          | 45%               | 45%              | 45%               |
| Vancomycin pulse-taper | 13%                          | 40%               | 40%              | 40%               |

Source: Assumption based on internal market data.

## Supplementary Fig. S1 PMPM costs by scenario



Anticipated scenario represents the scenario with uptake of VOS. Status quo represents the scenario in which VOS is not introduced to the formulary.

PMPM, per-member per-month; VOS, fecal microbiota spores, live-brpk (formerly SER-109).